Dermavant Sciences

Dermavant Sciences, Inc. is a biopharmaceutical company specializing in immunodermatology therapies. Committed to realizing the full potential of biomedical research, the company focuses on developing and commercializing novel first-in-class therapies to improve patients' lives. This includes enrolling patients with mild-to-moderate atopic dermatitis in the Phase 2 clinical study of RVT-501, an investigational topical phosphodiesterase-4 inhibitor, as well as planning the clinical development of RVT-201 (a novel caspase-1 inhibitor) as a topical treatment for various dermatological conditions.